In trying to cure some complex and formidable diseases, we know we can’t do it on our own. We like to partner with researchers, clinicians and organizations that can help us to develop and deliver better products to more patients and we welcome your interest: email@example.com.
The strategic collaboration and license agreement with bluebird bio was initiated in December 2017. bluebird bio is a clinical stage gene therapy company working in gene editing and cancer immunotherapy.
In 2017, TC BioPharm agreed to license technology and work alongside clinical researchers at University College London in CAR-T for the treatment of cancers using CAR-T. The academics at UCL’s Great Ormond Street Institute of Child Health, Professor John Anderson and Dr Jonathan Fisher are leading a pioneering research group developing novel chimeric antigen receptor therapies.
Sottish Enterprise support the economic growth of Scotland across a number of industries, including the life sciences sector. As an early stage strategic investor, Scottish Enterprise have supported the continued growth of TC BioPharm.
Supported by Medical Research Scotland (MRS), TC BioPharm are collaborating with the University of Glasgow in candidate discovery with the goal of creating CAR-T drugs for diseases with acute clinical needs, leveraging antigen targets previously considered “undruggable”.
The NIPRO Corporation and TC BioPharm established a strategic collaboration in 2018 to co-develop a novel immunotherapy product using TC BioPharm’s safe CAR-T platform. NIPRO is a manufacturer of innovative medical products for patient care.
In 2019, Trinity College Dublin and TC BioPharm announced a collaboration to accelerate GMP production of unconventional subtypes of GD T cells for the development of cancer therapies. The collaboration with Dublin’s School of Medicine, Trinity College, leverages extensive experience gained by Dr Derek Doherty related to the biology and culture expansion of V delta 1 GDT cells.
The strategic collaboration with Scotia Biologics began in 2018. Using Scotia’s expertise in antibody generation and engineering the two organizations are producing a range of novel proprietary tumor-specific antibodies for TC BioPharm’s CAR-T platform.
In 2017, TC BioPharm was selected for funding from the European Union’s Horizon 2020 (H2020) research and innovation program with the award of a grant of €4m. The H2020 grant is enabling rapid progress of the generation of allogeneic versions of TC BioPharm’s innovative GDT cell therapies.